ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

PNT Company Profile and Key Details

NASDAQ : PNT

POINT Biopharma Global Inc.

$12.50

0.02+0.16%

Open: 4:00 PM

Not Actively Trading

69.26

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

PNT Stock Price Chart

Stock Price Today

POINT Biopharma Global Inc. (PNT) stock surged +0.16%, trading at $12.50 on NASDAQ, up from the previous close of $12.48. The stock opened at $12.50, fluctuating between $12.49 and $12.51 in the recent session.

Stock Snapshot

12.48

Prev. Close

12.5

Open

1.33B

Market Cap

106.57M

Number of Shares

12.49

Day Low

12.51

Day High

11.363636363636363

P/E Ratio

82.08%

Free Float in %

1.1

EPS (TTM)

4.01

Book Value

0.88

Cash Flow per Share

3.29M

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 29, 2023	12.50	12.50	12.50	12.50	0
Dec 28, 2023	12.50	12.50	12.50	12.50	0
Dec 27, 2023	12.50	12.50	12.50	12.50	0
Dec 26, 2023	12.50	12.51	12.49	12.50	3.29M
Dec 22, 2023	12.47	12.51	12.45	12.48	3.48M
Dec 21, 2023	12.48	12.48	12.46	12.47	1.88M
Dec 20, 2023	12.46	12.48	12.46	12.47	2.14M
Dec 19, 2023	12.45	12.47	12.43	12.45	9.89M
Dec 18, 2023	12.46	12.49	12.44	12.45	36.69M
Dec 15, 2023	13.81	14.03	13.58	14.02	6.1M
Dec 14, 2023	14.30	14.30	13.69	13.71	2.16M
Dec 13, 2023	14.17	14.35	13.98	14.23	4.35M
Dec 12, 2023	14.00	14.24	13.86	14.16	2.2M
Dec 11, 2023	14.15	14.15	13.79	14.01	850.18K
Dec 08, 2023	14.05	14.16	13.88	14.06	1.57M
Dec 07, 2023	13.70	13.99	13.70	13.95	1.9M
Dec 06, 2023	13.83	13.95	13.62	13.81	1.36M
Dec 05, 2023	13.65	14.00	13.64	13.72	716.99K
Dec 04, 2023	13.74	13.84	13.63	13.75	854.48K
Dec 01, 2023	13.53	13.88	13.45	13.80	1.32M

Contact Details

Indianapolis, IN 46268

United States

Website: https://www.pointbiopharma.comContact: 647 812 2417

About Company

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Frequently Asked Questions

What is the current POINT Biopharma Global Inc. (PNT) stock price?

POINT Biopharma Global Inc. (NASDAQ: PNT) stock price is $12.50 in the last trading session. During the trading session, PNT stock reached the peak price of $12.51 while $12.49 was the lowest point it dropped to. The percentage change in PNT stock occurred in the recent session was 0.16% while the dollar amount for the price change in PNT stock was $0.02.

PNT's industry and sector of operation?

The NASDAQ listed PNT is part of Biotechnology industry that operates in the broader Healthcare sector. POINT Biopharma Global Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PNT?

Mr. Todd Hockemeyer B.E.
Executive Vice President of US Manufacturing Operations
Ms. Donna Husack B.A.
Vice President of HR
Ms. Jessica D. Jensen M.P.H., MPH
Executive Vice President of Clinical Devel.
Dr. Myra Rosario Herle Ph.D., R.Ph.
Executive Vice President of Regulatory Affairs
Mr. Chris Horvath
Executive Vice President of Commercial
Mr. Allan Charles Silber
Executive Chairman
Mr. Ari Shomair
Vice President of Corporation Affairs & Chief of Staff
Dr. Joe A. McCann Ph.D.
Chief Executive Officer & Director
Ms. Justyna Kelly M.Sc.
Chief Operating Officer
Dr. Matthew P. Vincent J.D., Ph.D.
Senior Vice President of Bus. Devel.
Ms. Melita Ann Sequeira B.Sc.
Senior Vice President of People & Culture
Dr. Neil E. Fleshner FRCSC, M.D., M.PH
Chief Medical Officer & Director
Mr. Bill Demers B.B.A., F.C.A., FCPA
Chief Financial Officer & Corporation Sec.

How PNT did perform over past 52-week?

PNT's closing price is 90.26% higher than its 52-week low of $6.57 where as its distance from 52-week high of $14.35 is -12.89%.

How many employees does PNT have?

Number of PNT employees currently stands at 129.

Link for PNT official website?

Official Website of PNT is: https://www.pointbiopharma.com

How do I contact PNT?

PNT could be contacted at phone 647 812 2417 and can also be accessed through its website. PNT operates from 4850 West 78th Street, Indianapolis, IN 46268, United States.

How many shares of PNT are traded daily?

PNT stock volume for the day was 3.29M shares. The average number of PNT shares traded daily for last 3 months was 3.85M.

What is the market cap of PNT currently?

The market value of PNT currently stands at $1.33B with its latest stock price at $12.50 and 106.57M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	129
Beta	0
Sales or Revenue	$226.58M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology